+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glucagon Like Peptide 2 Receptor - Pipeline Review, H1 2019

  • ID: 4772670
  • Drug Pipelines
  • 59 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Adocia SAS
  • Naia Ltd
  • Sosei Heptares
  • Therachon AG
  • Zealand Pharma AS
  • MORE
Glucagon Like Peptide 2 Receptor - Pipeline Review, H1 2019

Summary

According to the recently published report 'Glucagon Like Peptide 2 Receptor - Pipeline Review, H1 2019'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 12 molecules.

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

The report 'Glucagon Like Peptide 2 Receptor - Pipeline Review, H1 2019' outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 8 respectively. Report covers products from therapy areas Gastrointestinal, Toxicology and Metabolic Disorders which include indications Short Bowel Syndrome, Chemotherapy Effects, Diarrhea, Crohn's Disease (Regional Enteritis), Gastrointestinal Mucositis, Obesity and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
  • The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adocia SAS
  • Naia Ltd
  • Sosei Heptares
  • Therachon AG
  • Zealand Pharma AS
  • MORE
Introduction

Report Coverage

Glucagon Like Peptide 2 Receptor (GLP2R) - Overview

Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development

Adocia SAS

Hanmi Pharmaceuticals Co Ltd

Naia Ltd

PhaseBio Pharmaceuticals Inc

Sosei Heptares

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

Therachon AG

Zealand Pharma AS

Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles

apraglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elsiglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glepaglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXG-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15912 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Agonize GLP2R for Intestinal Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-7570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZPGG-72 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products

Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones

Featured News & Press Releases

Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference

Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study

Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome

Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome

Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome

Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide

May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.

Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland

Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome

Jan 23, 2018: Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.

Jan 22, 2018: Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference

Nov 14, 2017: Recruitment completed in trial to evaluate the optimal dosing frequency for Zealands long-acting GLP-2 analog glepaglutide

Oct 24, 2017: U.S. FDA Grants Orphan Drug Designation to Glepaglutide for the Treatment of Short Bowel Syndrome

Oct 12, 2017: Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Adocia SAS, H1 2019

Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019

Pipeline by Naia Ltd, H1 2019

Pipeline by PhaseBio Pharmaceuticals Inc, H1 2019

Pipeline by Sosei Heptares, H1 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019

Pipeline by Therachon AG, H1 2019

Pipeline by Zealand Pharma AS, H1 2019

Dormant Projects, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adocia SAS
  • Hanmi Pharmaceuticals Co Ltd
  • Naia Ltd
  • PhaseBio Pharmaceuticals Inc
  • Sosei Heptares
  • Takeda Pharmaceutical Co Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • Therachon AG
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
Adroll
adroll